Lecanemab and donanemab slow Alzheimer’s decline, but is the benefit worth the cost? New research shows that Lecanemab and Donanemab can delay cognitive decline and expand the independence of patients in daily activities.…
MHRA greenlights donanemab for early stage Alzheimer’s disease The Medicines and Healthcare products Regulatory Agency (MHRA) has today, October 23, 2024, approved a license for the medicine donanemab…
Concerns raised over safety and effectiveness of donanemab for Alzheimer’s treatment The safety and effectiveness of donanemab – an Alzheimer’s drug recently approved by the US Food & Drug Administration (FDA)…
